Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• The last two decades have seen a significant expansion in disease-modifying therapies for multiple sclerosis (MS).
• Early treatments included interferon-beta (IFNβ), glatiramer acetate, fumaric acid derivatives, and natalizumab.
• More recent innovations involve sphingosine 1-phosphate receptor (S1PR) modulators and immune reconstitution therapies.

Purpose of the Study:

• To review the evolution of multiple sclerosis (MS) treatments.
• To evaluate the advantages and disadvantages of second-generation MS therapies.
• To summarize emerging immunotherapies for MS.

Main Methods:

• Literature review of disease-modifying therapies for multiple sclerosis.
• Analysis of first-generation and second-generation drug classes.
• Discussion of current and future immunotherapy strategies in MS.

Main Results:

• First-generation therapies like interferon-beta and glatiramer acetate have limitations.
• Second-generation therapies, including pegylated interferon-beta, advanced CD20 depleting antibodies, and selective S1PR modulators, offer enhanced efficacy and safety profiles.
• Newer formulations and targeted approaches represent significant progress.

Conclusions:

• Second-generation therapies demonstrate improved efficacy and reduced side effects compared to parent drugs.
• Ongoing research focuses on developing more targeted and effective immunotherapies for multiple sclerosis.
• The field of multiple sclerosis treatment is rapidly evolving with promising future developments.